EGFR and neoplasm: Resistance to anti-EGFR therapies in head and neck cancer not only involves overexpression and activation of RTKs but also other factors, such as loss of tumor-suppressor genes, signaling by pattern recognition receptors, and activation of inflammatory pathways.